Journal article
Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity.
- Koch C Department of Tumor Biology, Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Kuske A Department of Tumor Biology, Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Joosse SA Department of Tumor Biology, Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Yigit G Institute of Human Genetics, University Medical Center Göttingen, Göttingen, Germany.
- Sflomos G ISREC - Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
- Thaler S European Centre for Angioscience (ECAS), Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
- Smit DJ Institute of Biochemistry and Signal Transduction, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Werner S Department of Tumor Biology, Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Borgmann K Radiobiology& Experimental Radiooncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Gärtner S Department of Tumor Biology, Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Mossahebi Mohammadi P Department of Tumor Biology, Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Battista L ISREC - Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
- Cayrefourcq L Laboratory of Rare Human Circulating Cells (LCCRH), University Medical Centre, Montpellier, France.
- Altmüller J Cologne Center for Genomics, University of Cologne, Cologne, Germany.
- Salinas-Riester G NGS Integrative Genomics Core Unit, Institute of Human Genetics, University Medical Center Göttingen, Göttingen, Germany.
- Raithatha K NGS Integrative Genomics Core Unit, Institute of Human Genetics, University Medical Center Göttingen, Göttingen, Germany.
- Zibat A Institute of Human Genetics, University Medical Center Göttingen, Göttingen, Germany.
- Goy Y Radiobiology& Experimental Radiooncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Ott L Department of Tumor Biology, Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Bartkowiak K Department of Tumor Biology, Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Tan TZ Cancer Science Institute of Singapore, National University of Singapore, Singapore City, Singapore.
- Zhou Q Institute of Human Genetics, Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz, Graz, Austria.
- Speicher MR Institute of Human Genetics, Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz, Graz, Austria.
- Müller V Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Gorges TM Department of Tumor Biology, Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Jücker M Institute of Biochemistry and Signal Transduction, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Thiery JP INSERM Unit 1186, Comprehensive Cancer Center, Institut Gustave Roussy, Villejuif, France.
- Brisken C ISREC - Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
- Riethdorf S Department of Tumor Biology, Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Alix-Panabières C Laboratory of Rare Human Circulating Cells (LCCRH), University Medical Centre, Montpellier, France.
- Pantel K Department of Tumor Biology, Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- 2020-07-16
Published in:
- EMBO molecular medicine. - 2020
English
Functional studies giving insight into the biology of circulating tumor cells (CTCs) remain scarce due to the low frequency of CTCs and lack of appropriate models. Here, we describe the characterization of a novel CTC-derived breast cancer cell line, designated CTC-ITB-01, established from a patient with metastatic estrogen receptor-positive (ER+ ) breast cancer, resistant to endocrine therapy. CTC-ITB-01 remained ER+ in culture, and copy number alteration (CNA) profiling showed high concordance between CTC-ITB-01 and CTCs originally present in the patient with cancer at the time point of blood draw. RNA-sequencing data indicate that CTC-ITB-01 has a predominantly epithelial expression signature. Primary tumor and metastasis formation in an intraductal PDX mouse model mirrored the clinical progression of ER+ breast cancer. Downstream ER signaling was constitutively active in CTC-ITB-01 independent of ligand availability, and the CDK4/6 inhibitor Palbociclib strongly inhibited CTC-ITB-01 growth. Thus, we established a functional model that opens a new avenue to study CTC biology.
- Language
-
- English
- Open access status
- gold
- Identifiers
-
- DOI 10.15252/emmm.201911908
- PMID 32667137
- Persistent URL
- https://folia.unifr.ch/global/documents/25892
Statistics
Document views: 70
File downloads: